Fair value · Grace Therapeutics, Inc. (GRCE) · updated 2026-09-03 · from 10-K FY2026
These methods need positive earnings and cash flow from the company’s SEC filings. The detailed valuation tools below still work with whatever has been filed.
10-K FY2026 · fiscal year ended 2026-03-31 · filed 2026-06-18 · accession 0001140361-26-025662
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q1 FY2027 (filed 2026-08-13).
Open this filing on sec.govAt least two methods need a usable value to draw a range with these inputs.
The two ranges are identical because every input sits on a preset.
We don’t tell you what GRCE is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has GRCE’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.
Discounted cash flow
N/A
No revenue in the latest annual filing
Preset inputs — revenue-driven DCF from the latest filing
Implied by today’s price
Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price.
Not solvable from the price — Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price. Showing preset inputs.
This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what GRCE has actually filed, and the AI chat will reason it through with you.
Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.
Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.
How long stage-1 growth lasts.
Slower growth after stage 1, before the terminal phase.
Growth forever after the two stages. Above ~3% is rarely justified.
The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.
| Year | Stage | FCF | Present value |
|---|---|---|---|
| 1 | Stage 1 | $-9M | $-9M |
| 2 | Stage 1 | $-10M | $-9M |
| 3 | Stage 1 | $-10M | $-9M |
| 4 | Stage 1 | $-11M | $-8M |
| 5 | Stage 1 | $-11M | $-8M |
| 6 | Stage 2 | $-12M | $-8M |
| 7 | Stage 2 | $-12M | $-8M |
| 8 | Stage 2 | $-12M | $-7M |
| 9 | Stage 2 | $-13M | $-7M |
| 10 | Stage 2 | $-13M | $-7M |
Inputs from the filing
10-K FY2026 · period ended 2026-03-31 · filed 2026-06-18 · accession 0001140361-26-025662 · sec.gov
Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for GRCE
Download the full GRCE valuation report (PDF) — free
DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.